Biotoxtech

Biotoxtech is the only Kosdak-listed company that has gone public as a domestic CRO in China. In 2010, it was selected as a representative CRO of South Korea and successfully passed the GLP inspection of the OECD Mutual Joint Visit (MJV). The company’s businesses include safety evaluations of synthetic drugs, biopharmaceuticals, cell therapy, gene therapy, health functional foods, chemicals, and pesticides; PK/TD, ADME, RI analysis; efficacy testing and substance screening; clinical pathology and histopathology distribution; development of new materials; and consultation for non-clinical trials.